The objective was to determine the research status and hotspots of seasonal affective disorders (SAD) based on bibliometric tools, which will contribute to the further research in this field. We used bibliometric tools CiteSpace and VOSviewer to conduct visual quantitative analysis on 465 SAD literatures in the Web of Science core database from 2008 to 2023 from multiple perspectives such as collaboration network, keywords, and literature citations. At the same time, we used Microsoft Word to...

Seasonal affective disorder (SAD) is typically associated with winter; however, its less common variant, summertime depression, presents with depressive episodes during the summer months. We report a case of a 46-year-old male patient with recurrent summertime depressive episodes characterized by low mood, fatigue, anhedonia, insomnia, and loss of appetite, each resolving with the onset of the winter season. Our patient's history of summertime depression aligned with the atypical SAD symptoms,...

Bupropion is an antidepressant medication that has received FDA approval for the treatment of depression and seasonal affective disorder and as an aid for smoking cessation. Since its approval in 1985, bupropion has been utilized off-label for various conditions, including antidepressant-induced sexual dysfunction, depression associated with bipolar disorder, obesity, and ADHD in pediatric patients. This activity reviews bupropion's clinical applications, including indications, dosing, mechanism...

Depressive disorders are characterized by disturbances in light signal processing. More specifically, an alteration of the melanopsin response is suggested. The post-illumination pupillary response (PIPR) to blue light (post-blue PIPR) is increasingly used as a marker of the activity of intrinsically photosensitive melanopsin ganglion cells (ipRGCs). We hypothesized that individuals with Major Depressive Episode (MDE) who exhibited a higher vulnerability to season patterns showed a decreased...